Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna uses its mRNA platform to design products that instruct cells to produce proteins or immune responses relevant to prevention and treatment. The company also works with manufacturing and commercialization capabilities to support product development and distribution across major healthcare markets. Headquartered in Cambridge, Massachusetts, Moderna plays a significant role in the biopharmaceutical industry by advancing a new class of medicines across vaccines and therapeutics.
Omsetning og resultat (USD)
Gj.sn. kursmål: $122,67

Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
The Motley Fool · 14. nov. 2026

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
Zacks Investment Research · 13. nov. 2026

MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
Zacks Investment Research · 12. nov. 2026
Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna uses its mRNA platform to design products that instruct cells to produce proteins or immune responses relevant to prevention and treatment. The company also works with manufacturing and commercialization capabilities to support product development and distribution across major healthcare markets. Headquartered in Cambridge, Massachusetts, Moderna plays a significant role in the biopharmaceutical industry by advancing a new class of medicines across vaccines and therapeutics.
Omsetning og resultat (USD)
Gj.sn. kursmål: $122,67

Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
The Motley Fool · 14. nov. 2026

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
Zacks Investment Research · 13. nov. 2026

MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
Zacks Investment Research · 12. nov. 2026